GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Total Payout Yield %

BOLD (Boundless Bio) Total Payout Yield % : 0.00 (As of Jul. 17, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Boundless Bio's current Total Payout Yield % is 0.00%.


Boundless Bio Total Payout Yield % Historical Data

The historical data trend for Boundless Bio's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Total Payout Yield % Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Total Payout Yield %
- - - -143.81

Boundless Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Payout Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Boundless Bio's Total Payout Yield %

For the Biotechnology subindustry, Boundless Bio's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boundless Bio's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Boundless Bio's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Boundless Bio's Total Payout Yield % falls into.


;
;

Boundless Bio Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Boundless Bio's Total Payout Yield % for the fiscal year that ended in Dec. 2024 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (0 + 93 + 0) / 64.67
=-143.81%

Boundless Bio's annualized Total Payout Yield % for the quarter that ended in Mar. 2025 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (0 + 0 + 0) * 4 / 33.673
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Boundless Bio Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.


Boundless Bio Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Boundless Bio Business Description

Traded in Other Exchanges
N/A
Address
10955 Alexandria Way, Suite 100, San Diego, CA, USA, 92121
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.